32066-29-8

Basic information

• Product Name: 4-HYDROXYBENZOYLACETIC ACID METHYL ESTER
• Synonyms: hydroxybenzoylaceticacidmethylester;METHYL (4-HYDROXYBENZOYL)ACETATE;4-HYDROXYBENZOYLACETIC ACID METHYL ESTER;4-HYDROXYBENZOYLACETIC ACID METHYL ESTER 93+%;Benzenepropanoic acid, 4-hydroxy-b-oxo-, Methyl ester;methyl 3-(4-hydroxyphenyl)-3-oxopropanoate
• CAS NO: 32066-29-8
• Molecular Formula: C₁₀H₁₀O₄
• Molecular Weight: 194.18
• Mol File: 32066-29-8.mol

Chemical Properties

• Melting Point: 90°C
• Boiling Point: 340°C at 760 mmHg
• Flash Point: 135.5°C
• Appearance: /
• Density: 1.245g/cm³
• Vapor Pressure: 4.48E-05mmHg at 25°C
• Refractive Index: 1.543
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• PKA: 7.79±0.15(Predicted)
• CAS DataBase Reference: 4-HYDROXYBENZOYLACETIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-HYDROXYBENZOYLACETIC ACID METHYL ESTER(32066-29-8)
• EPA Substance Registry System: 4-HYDROXYBENZOYLACETIC ACID METHYL ESTER(32066-29-8)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Safety Statements: 24/25
• Hazardous Substances Data: 32066-29-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Hydroxybenzoylactic acid methyl ester is used as a pharmaceutical intermediate for the production of various drugs and pharmaceutical products. It is utilized to modify and enhance the properties of active ingredients, improving their efficacy and safety.
Used in Organic Synthesis:
4-Hydroxybenzoylactic acid methyl ester is used as a key component in organic synthesis, contributing to the development of new chemical compounds and materials. Its unique structure and reactivity make it a valuable building block for the synthesis of complex organic molecules.
Used in Chemical Research:
4-Hydroxybenzoylactic acid methyl ester is employed in chemical research to explore its potential applications and properties. Researchers investigate its reactivity, stability, and interactions with other compounds to gain insights into its potential uses in various fields, including pharmaceuticals, materials science, and environmental chemistry.

InChI:InChI=1/C10H10O4/c1-14-10(13)6-9(12)7-2-4-8(11)5-3-7/h2-5,11H,6H2,1H3

Upstream product

• 616-38-6 carbonic acid dimethyl ester 
• 99-93-4 4-Hydroxyacetophenone 
• 54696-05-8 4'-benzyloxy-acetophenone 
• 705939-73-7 methyl 3-[4-(benzyloxy)phenyl]-3-oxopropanoate 
• 22027-50-5 methyl 3-(4-methoxybenzoyl)acetate 

Downstream Products

• 501334-19-6 methyl 3-[4-(tert-butyldimethylsilyloxybenzyl)phenyl]-3-oxopropanoate 
• 189999-47-1 Methyl 3-Oxo-3-(4-Pivaloyloxyphenyl) Propionate 
• 1032392-52-1 methyl 3-(ethoxyimino)-3-(4-hydroxyphenyl)propanoate 
• 733748-00-0 1-{6-[4-(2-methoxycarbonyl-acetyl)-phenoxy]-5-nitro-pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester 
• 136634-54-3 methyl (4-hydroxyphenyl)propynoate 
• 1356599-24-0 (3E,3Z)-3-(methoxyimino)-3-{4-[(4-{[(2Z)-2-(methoxyimino)-2-phenylethyl]oxy}benzyl)oxy]phenyl}propanoic acid 
• 1356599-74-0 3-hydroxy-3-{4-[(4-{[(2Z)-2-(methoxyimino)-2-phenylethyl]oxy}benzyl)oxy]phenyl}propanoic acid 
• 1356599-76-2 (3Z)-3-{4-[(4-{[(2E,2Z)-2-(methoxyimino)-2-phenylethyl]oxy}benzyl)oxy]phenyl}-3-[(prop-2-en-1-yloxy)imino]propanoic acid 
• 1356600-42-4 methyl (3E,3Z)-3-(4-hydroxyphenyl)-3-(methoxyimino)propanoate 
• 1356602-45-3 methyl 3-{4-[(4-{[(2Z)-2-(methoxyimino)-2-phenylethyl]oxy}benzyl)oxy]phenyl}-3-oxopropanoate 
• 1404447-06-8 5-(4-hydroxyphenyl)-2-methyl-3-phenylpyrazolo[1,5-a]pyrimidin-7(4H)-one 
• 1441058-24-7 methyl 3-oxo-3-(4-(4,4,4-trifluorobutoxy)phenyl)propanoate 
• 1441058-26-9 methyl 1-(4-(4,4,4-trifluorobutoxy)benzoyl)cyclopropanecarboxylate 
• 1441058-28-1 methyl 1-((benzylimino)(4-(4,4,4-trifluorobutoxy)phenyl)methyl)cyclopropane carboxylate 

Relevant articles and documents

Compound and its as L-type calcium channel blocker or/and application of acetylcholine esterase inhibitors

Disclosed in this invention are compounds and the uses as L-type calcium channel blocker and/or acetylcholinesterase inhibitor thereof. The uses of said compounds in the manufactures of a medicament for the treatment of cardiovascular diseases, apoplexy or senile dementia are also disclosed in the present invention.

HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK

Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.

AGONISTS OF GPR40

The present invention relates to compounds that have the ability to modulate the activity of GPR40 and are there-fore useful in the treatment of GPR40 related disorders. In addition the invention relates to the compounds, methods for their preparation, pharmaceutical compositions containing the compounds and the uses of these compounds in the treatment of certain disorders related to GPR40 activity.

Phosphorous prodrugs and therapeutic delivery systems using same

The composition and methods of synthesis of phosphorus prodrugs are described. These methods can be used to convert negatively charged phosphorous bearing drugs into neutrally charged; lipid soluble prodrugs which are able to passively diffuse into cells